Global EditionASIA 中文双语Français
China
Home / China / Health

Medical institutions ordered to cooperate in recall of hypertension drug

By WANG XIAODONG | chinadaily.com.cn | Updated: 2018-07-30 14:07
Share
Share - WeChat

Medical institutions must cooperate with the authorities in the recall of hypertension drugs containing a carcinogenic impurity, the National Health Commission said on Monday. 

On Sunday, China's top drug regulator urged provincial drug authorities to supervise a recall by pharmaceutical companies of all valsartan produced with raw materials supplied by Zhejiang Huahai Pharmaceutical Co, which is based in Linhai, Zhejiang province. 

Huahai reported to the State Drug Administration on July 6 that it had found traces of NDMA, a substance that may cause cancer, in valsartan it produced. The company has recalled all its affected products from the Chinese market.

The National Health Commission said on Monday that no medical institutions could use valsartan drugs covered by the recall, but they can use valsartan made by other companies or other hypertension drugs, based on advice from doctors.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US